Support PenkeAltimmune Inc - Trending symbols
Latest News of Altimmune Inc
| Date | Title | Read |
|---|---|---|
| 2025-09-11 23:59 | Faruqi & Faruqi Reminds Altimmune Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 6, 2025 - ALT | Read |
| 2025-09-11 22:22 | Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before October 6, 2025 to Discuss Your Rights – ALT | Read |
| 2025-09-10 03:16 | ROSEN, A LONGSTANDING LAW FIRM, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT | Read |
| 2025-09-07 18:10 | Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm | Read |
| 2025-09-06 16:27 | INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Altimmune, Inc. of Class Action Lawsuit and Upcoming Deadlines - ALT | Read |
| 2025-09-05 22:56 | Lost Money on Altimmune, Inc. (ALT)? Join Class Action Suit Seeking Recovery – Contact Levi & Korsinsky | Read |
| 2025-09-05 20:23 | ROSEN, LEADING INVESTOR COUNSEL, Encourages Altimmune, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - ALT | Read |
| 2025-09-03 17:09 | DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune | Read |
| 2025-09-03 14:21 | Bragar Eagel & Squire, P.C. Reminds Investors of Novo, Altimmune, SelectQuote, and Spectrum that Lawsuits Have Been Filed and Encourages Investors to Contact the Firm | Read |
| 2025-08-22 15:45 | SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Altimmune | Read |
Trends
| 2024-06-30 | 2024-09-30 | 2024-12-31 | 2025-03-31 | 2025-06-30 | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Profit | 5 | 0 | 5 | 0 | 5 | 0 | 5 | -30 | -25 | |
| Reconciled Depreciation | -236 | -120 | -356 | -149 | -505 | -47 | -552 | 2,442 | 1,890 | |
| Total Other Income Expense Net | 1,434 | 251 | 1,685 | -1,572 | 113 | 1,756 | 1,869 | -12,306 | -10,437 | |
| Total Revenue | 10,331 | -4,530 | 5,801 | 2,384 | 8,185 | -3,775 | 4,410 | -4,478 | -68 | |
| Income Tax Expense | -288 | 91 | -197 | -1,237 | -1,434 | -249 | -1,683 | 2,303 | 620 | |
| Research Development | 8,951 | 2,927 | 11,878 | 1,395 | 13,272 | 15,933 | 29,206 | -83,487 | -54,282 | |
| Income before Tax | -10,732 | -4,132 | -14,864 | -9,963 | -24,827 | -8,684 | -33,511 | 106,615 | 73,104 | |
| Net Income | -10,622 | -4,242 | -14,864 | -9,963 | -24,827 | -8,684 | -33,511 | 106,615 | 73,104 | |
| Selling General Administrative | 4,112 | -291 | 3,821 | -163 | 3,659 | 497 | 4,156 | -15,777 | -11,621 | |
| EBITDA | -10,651 | -4,127 | -14,778 | -9,951 | -24,729 | -8,464 | -33,193 | 106,231 | 73,038 | |
| Interest Expense | 2 | 10 | 12 | 11 | 22 | 11 | 33 | -100 | -67 | |
| Total Operating Expenses | 13,063 | 2,637 | 15,699 | 1,232 | 16,931 | 16,431 | 33,362 | -99,252 | -65,891 |
Comments
How you think about this?